Dr. Roy is an Internal Medicine- and Addiction Medicine-trained physician and health services researcher. Her clinical and academic interests are in addressing barriers to accessing medications for opioid use disorder and in developing and expanding the addiction medicine workforce. She directs the Addiction Medicine Consult Service at UPMC Presbyterian Hospital, sees patients at the Internal Medicine Recovery and Engagement Program (IM-REP), and serves as core faculty for the UPMC Addiction Medicine Fellowship.
Dr. Roy enjoys rock climbing and is the Pittsburgh Ambassador for the Ladies Climbing Coalition. She is also an active member of the Bengali Association of Pittsburgh.
Education & Training
- BA (Biology), New York University, 2009
- MD (Medicine), Stony Brook University School of Medicine, 2013
- MSc (Health Services and Systems Research), Boston University School of Public Health, 2019
- Internal Medicine Residency, Boston University School of Medicine, 2016
- Chief Residency (Internal Medicine), Boston University School of Medicine, 2017
- Addiction Medicine Fellowship, Boston University School of Medicine, 2019
- Integrated Care for Addiction, HIV, and HCV Research and Education (T32), Boston University School of Public Health, 2019
Representative Publications
Roy PJ, Kim KC, Suda K, Luo J, Wang X, Olejniczak D, Liebschutz JM. Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design. Drug Alcohol Depen Rep. 2023 Mar;6:100135.
COVID-19 reduced treatment disruptions among stably-treated patients on buprenorphine and had no impact on buprenorphine prescribing overall one year after the beginning of the pandemic.
Roy PJ, Price R, Choi S, Weinstein ZM, Bernstein E, Cunningham CO, Walley AY. Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. Drug Alcohol Depend. 2021 Jul 1;224:108703.
At hospital discharge, patients were more likely to follow-up with buprenorphine care the earlier their appointments were post-discharge.
Roy PJ, Weltman M, Dember LM, Liebschutz J, Jhamb M. Pain management in patients with chronic kidney disease and end-stage kidney disease. Curr Opin Nephrol Hypertens. 2020 Nov;29(6):671-680.
Chronic pain is common among people with CKD and ESKD. While non-pharmacologic and non-opioid therapies are preferred, buprenorphine, methadone, fentanyl, hydromophone, and oxycodone are the safest opioids to use in this popoulation.
Roy PJ, Stein MD. Offering emergency buprenorphine without a prescription. JAMA. 2019 Aug 13;322(6):501-502.
Buprenorphine is safe and effective - it should be offered without a prescription to improve access.
Click here for a more complete bibliography of Dr. Roy’s works.
Research Interests
- Impact of prescribing policy on buprenorphine dispensing
- Oral health impact on medications for opioid use disorder
- Alternative treatments for substance use disorders